4-(4-Fluorophenyl)-5-(2-methylthiopyrimidin-4-yl)oxazole | 742078-84-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 4-(4-Fluorophenyl)-5-(2-methylthiopyrimidin-4-yl)oxazole
• 英文别名: 4-(4-Fluorophenyl)-5-(2-methylsulfanylpyrimidin-4-yl)-1,3-oxazole
• CAS: 742078-84-8
• 化学式: C₁₄H₁₀FN₃OS
• 分子量: 287.317
• InChiKey: PLZCQAICTYYNQD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  20
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  77.1
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  4-(4-Fluorophenyl)-5-(2-methylthiopyrimidin-4-yl)oxazole 在 正丁基锂 、 溶剂黄146 、 间氯过氧苯甲酸 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 0.17h， 生成 4-[4-(4-Fluoro-phenyl)-5-(2-methanesulfinyl-pyrimidin-4-yl)-oxazol-2-yl]-1-methyl-piperidin-4-ol
  参考文献：
  名称：

  Novel p38 inhibitors with potent oral efficacy in several models of rheumatoid arthritis

  摘要：

  A library of trisubstituted oxazoles, thiazoles, imidazoles (1,2,4- and 2,4,5-substituted) and imidazo[1,2-b]pyridines was prepared and evaluated in vitro as p38alpha inhibitors and in vivo in several models of rheumatoid arthritis. Four structures 32, 37, 45 and 59-were identified as potent inhibitors of p38alpha with high efficacy in the LPS induced TNFalpha release model in the mouse, the adjuvant induced arthritis and the collagen induced arthritis in the rat with ED(50)s between 1.0 and 9.5 mg/kg p.o. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2004.03.106
• 作为产物：
  描述：

  2-bromo-1-(4-fluorophenyl)-2-(2-methylsulfanylpyrimidin-4-yl)ethanone 、 formamide 在 硫酸 作用下， 反应 0.25h， 生成 4-(4-Fluorophenyl)-5-(2-methylthiopyrimidin-4-yl)oxazole
  参考文献：
  名称：

  Novel p38 inhibitors with potent oral efficacy in several models of rheumatoid arthritis

  摘要：

  A library of trisubstituted oxazoles, thiazoles, imidazoles (1,2,4- and 2,4,5-substituted) and imidazo[1,2-b]pyridines was prepared and evaluated in vitro as p38alpha inhibitors and in vivo in several models of rheumatoid arthritis. Four structures 32, 37, 45 and 59-were identified as potent inhibitors of p38alpha with high efficacy in the LPS induced TNFalpha release model in the mouse, the adjuvant induced arthritis and the collagen induced arthritis in the rat with ED(50)s between 1.0 and 9.5 mg/kg p.o. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2004.03.106

文献信息

• Oxazoles for treating cytokine mediated diseases
  申请人：SmithKline Beecham Corporation

  公开号：US20020169173A1

  公开（公告）日：2002-11-14

  This invention relates to the novel oxazole compounds of Formula (I) and novel pharmaceutical compositions comprising a compound of Formula (I) and a pharmaceutically acceptable diluent or carrier. This invention alsso relates to a method of inhibiting cytokines and the treatment of cytokine mediated diseases, in mammals, thereby by administration of an effective amount of a compound according to Formula (I).

  本发明涉及公式(I)的新型噁唑化合物和包含公式(I)化合物和药学上可接受的稀释剂或载体的新型药物组合物。本发明还涉及通过给哺乳动物以公式(I)化合物的有效量来抑制细胞因子和治疗细胞因子介导的疾病的方法。
• Pyridyl-oxazoles and their use as cytokines inhibitors
  申请人：SMITHKLINE BEECHAM CORPORATION

  公开号：EP1306377A2

  公开（公告）日：2003-05-02

  This invention relates to the novel oxazole compounds of Formula (I) and novel pharmaceutical compositions comprising a compound of Formula (I) and a pharmaceutically acceptable diluent or carrier. This invention also relates to a method of inhibiting cytokines and the treatment of cytokine mediated diseases, in mammals, thereby by administration of an effective amount of a compound according to Formula (I).

  本发明涉及式(I)的新型噁唑化合物和由式(I)化合物和药学上可接受的稀释剂或载体组成的新型药物组合物。 本发明还涉及一种抑制细胞因子和治疗细胞因子介导的疾病的方法，该方法通过在哺乳动物体内施用有效量的根据式（I）的化合物来实现。
• OXAZOLES FOR TREATING CYTOKINE MEDIATED DISEASES
  申请人：SMITHKLINE BEECHAM CORPORATION

  公开号：EP0727998A1

  公开（公告）日：1996-08-28
• EP0727998A4
  申请人：——

  公开号：EP0727998A4

  公开（公告）日：1997-03-19
• US6288062B1
  申请人：——

  公开号：US6288062B1

  公开（公告）日：2001-09-11